SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNationwide Ccds Regulatory News (NBS)

Share Price Information for Nationwide Ccds (NBS)

Share Price is delayed by 15 minutes
Get Live Data
129.00    0.00 (0.00%)
Bid:
127.00
Ask:
131.00
Spread: 4.00 (3.15%)
Market Cap: £1.18b
NBS Live PriceLast checked at - London Stock Exchange

Intraday Nationwide Ccds Share Chart

Revocation of Sub-consolidation Direction

2 Dec 2025 07:00

RNS Number : 7820J
Virgin Money UK PLC
02 December 2025
 

 

 

 

Virgin Money UK PLC (incorporated with limited liability in England and Wales, registered number 09595911)

 

(the "Issuer")

 

LEI: 213800ZK9VGCYYR6O495

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION

2 December 2025

 

ANNOUNCEMENT

 

to the holders of the Issuer's outstanding

 

£350,000,000 8.250 per cent. Fixed Rate Reset Perpetual Subordinated Contingent Convertible Notes, of which £10,075,000 remains outstanding

(ISIN: XS2486863595)

£350,000,000 11.000 per cent. Fixed Rate Reset Perpetual Subordinated Contingent Convertible Notes, of which £170,147,000 remains outstanding

(ISIN: XS2718145779)

(together, the "Outstanding AT1 Instruments")

 

In September 2024, as part of the arrangements for the acquisition of the Issuer by Nationwide Building Society ("Nationwide") (the "Acquisition"), it was announced that the Prudential Regulation Authority ("PRA") intended to apply sub-consolidated prudential requirements to the Issuer until 31 December 2028. These sub-consolidated prudential requirements have applied since the completion of the Acquisition on 1 October 2024 ("Completion") pursuant to a direction imposed by the PRA on the Issuer under section 192C of the Financial Services and Markets Act 2000 (as amended) (the "Direction"). As a result, from Completion, outstanding externally held own funds instruments issued by the Issuer were, subject to applicable deductions, eligible to meet the consolidated capital requirements applicable to Nationwide.

 

Since Completion, the Nationwide group has simplified and aligned its capital structure, including by way of the Issuer's consent solicitations and tender offers (announced on 3 June 2025) and its early redemption of certain notes pursuant to their contractual terms. Clydesdale Bank PLC, the principal subsidiary of the Issuer is also currently preparing to transfer substantially all of its assets and liabilities to Nationwide pursuant to a banking business transfer, which (subject to court sanction) is proposed to take effect on 2 April 2026. As a result, the Direction is no longer required. Accordingly, on 1 December 2025, the PRA revoked the Direction.

Revocation of the Direction has the effect that the Outstanding AT1 Instruments cease to be eligible as own funds of the Issuer on a sub-consolidated basis or of Nationwide on a consolidated basis. As a consequence, certain provisions of the Outstanding AT1 Instruments which apply by virtue of their status as own funds instruments no longer apply under the terms of those instruments.

 

The Outstanding AT1 Instruments, together with the Issuer's outstanding externally held eligible liabilities instruments, will continue to be eligible to meet Nationwide's consolidated minimum requirement for own funds and eligible liabilities (MREL) until 31 December 2028, in accordance with the discretion applied by the Bank of England at the time of the Acquisition.

 

This announcement contains inside information as defined in Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR") and is disclosed in accordance with the Issuer's obligations under Article 17 of MAR. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain.

 

Announcement authorised for release by Jason Wright, Company Secretary

 

For further information please contact:

 

Vikas Sidhu

Head of Investor Relations and Treasury Sustainability

+44 (0) 7738 273 287

Vikas.Sidhu@nationwide.co.uk 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCTBBMTMTIMTRA
Date   Source Headline
12th Jun 20262:02 pmRNSPublication of a Prospectus
12th Jun 202611:31 amRNSPublication of Registration Document
12th Jun 202611:24 amRNSPublication of a Prospectus
9th Jun 202611:15 amRNSAdmission to Trading
8th Jun 202611:52 amRNSNOTICE TO NOTEHOLDERS
5th Jun 20262:58 pmRNSPublication of Final Terms
21st May 202612:33 pmRNSPublication of a Supplementary Prospectus
21st May 20267:00 amRNSPreliminary Results Announcement
6th May 20263:12 pmRNSPublication of Final Terms
21st Apr 20263:38 pmRNSPublication of Final Terms
21st Apr 202610:20 amRNSCancellation of Listing
20th Apr 202612:38 pmRNSNotice to Covered Bondholders
9th Apr 202611:06 amRNSPublication of a Supplementary Prospectus
7th Apr 20267:00 amRNSPart VII Transfer & Board changes
20th Mar 20268:48 amRNSRedemption of Securities
3rd Mar 202611:50 amRNSAdmission to Trading
3rd Mar 202611:44 amRNSAdmission to Trading
27th Feb 20265:18 pmRNSPublication of Final Terms
27th Feb 20263:56 pmRNSPublication of Final Terms
26th Feb 202611:00 amRNSPart VII Transfer
24th Feb 20269:51 amRNSAdmission to Trading
20th Feb 20269:47 amRNSPublication of Final Terms
19th Feb 202610:04 amRNSAdmission to Trading
17th Feb 20269:56 amRNSAdmission to Trading
17th Feb 20269:46 amRNSPublication of Final Terms
13th Feb 20262:04 pmRNSPublication of Final Terms
13th Feb 20268:15 amRNSPost Stabilisation Notice
3rd Feb 20262:41 pmRNSAdmission to Trading
30th Jan 20261:00 pmRNSPublication of Final Terms
16th Jan 20261:21 pmRNSPublication of Final Terms
8th Jan 20261:49 pmRNSPublication of Final Terms
8th Jan 20267:00 amRNSDirectorate change
7th Jan 202610:49 amRNSPre Stabilisation Notice
19th Dec 202511:00 amRNSDirectorate change
19th Dec 202511:00 amRNSDirectorate change
16th Dec 20252:42 pmRNSPublication of a Supplementary Prospectus
2nd Dec 20257:10 amRNSResponse to 2025 BOE Capital Stress Test Results
2nd Dec 20257:00 amRNSRevocation of Sub-consolidation Direction
20th Nov 202511:47 amRNSPublication of Supplement
20th Nov 20257:00 amRNSInterim Results September 2025
14th Nov 202511:00 amRNSPart VII Transfer
21st Oct 20251:08 pmRNSPublication of Final Terms
10th Oct 202512:52 pmRNSPublication of Final Terms
1st Oct 20257:00 amRNSConfirmation of Post-Offer Intention Statements
30th Sep 202510:03 amRNSBoard Changes
30th Sep 20259:43 amRNSBoard Changes
30th Sep 20257:00 amRNSBoard Changes
26th Sep 20252:49 pmRNSPublication of Final Terms
16th Sep 20251:48 pmRNSPublication of Final Terms
8th Sep 202511:27 amRNSPublication of Final Terms

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.